Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Equity Average (2021 - 2025)

Krystal Biotech's Equity Average history spans 5 years, with the latest figure at $1.2 billion for Q4 2025.

  • For Q4 2025, Equity Average rose 28.67% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, up 28.67%, while the annual FY2025 figure was $1.1 billion, 25.56% up from the prior year.
  • Equity Average for Q4 2025 was $1.2 billion at Krystal Biotech, up from $1.1 billion in the prior quarter.
  • Across five years, Equity Average topped out at $1.2 billion in Q4 2025 and bottomed at $413.4 million in Q3 2021.
  • The 5-year median for Equity Average is $704.5 million (2023), against an average of $722.5 million.
  • The largest annual shift saw Equity Average fell 11.41% in 2023 before it surged 55.95% in 2024.
  • A 5-year view of Equity Average shows it stood at $500.9 million in 2021, then increased by 6.11% to $531.5 million in 2022, then surged by 44.36% to $767.3 million in 2023, then increased by 19.4% to $916.1 million in 2024, then increased by 28.67% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Equity Average are $1.2 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.0 billion (Q2 2025).